Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Treatment for CLL may involve various approaches, including chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Companies involved in CLL treatment play crucial roles in developing and providing medications, therapies, and diagnostic tools to manage the disease.
Pirtobrutinib (Rozlytrek®): In December 2023, the FDA granted accelerated approval to pirtobrutinib for adults with CLL or small lymphocytic lymphoma (SLL) who previously received at least two lines of prior therapy, including a BTK inhibitor and a BCL2 inhibitor. This signifies the first non-covalent BTK inhibitor approved for CLL and represents a significant milestone for targeted therapy options.
Venetoclax (Venclexta®): In October 2023, the FDA approved venetoclax in combination with obinutuzumab for the frontline treatment of patients with CLL and a specific genetic mutation (17p deletion). This expands the use of venetoclax beyond relapsed/refractory CLL and offers a highly effective option for newly diagnosed patients.
Zanubrutinib (Brukinsa®): Positive results from the Phase 3 ELEVATE-RR trial evaluating zanubrutinib in combination with venetoclax for previously untreated CLL were presented at ASCO 2023. This combination demonstrated superior progression-free survival and minimal residual disease compared to standard chemoimmunotherapy.
List of Chronic Lymphocytic Leukemia Treatment Key Companies in the Market
Chronic Lymphocytic Leukemia Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)